• 中国资本市场开放出大招 跨境证券投资更便利 2019-10-13
  • 世卫将“游戏障碍”列为新疾病 哪些症状可被确诊? 2019-10-13
  • 景区去门票化积弊短期难除 如何摆脱门票依赖? 2019-10-08
  • 东风路老旧小区欲华丽变身 微改造项目勘察设计已招标 ——凤凰网房产广州 2019-10-08
  • 翔龙无人机服役后首次曝光,大幅提升空军情报收集能力 2019-09-19
  • 证监会去年对外公开监管信息14560条 2019-09-19
  • 人民网欧洲中心分社记者报道集 2019-09-06
  • 图解:短视频平台频遭约谈敲响警钟,野蛮生长要不得! 2019-09-06
  • 中考期间广州部分公交线路有调整 2019-09-01
  • 减肥必备!这十种食物饱口福还能吃出好身材 2019-09-01
  • “蛟龙” 吸引世界目光(砥砺奋进的五年·重大工程巡礼) 2019-08-19
  • 李克强:扩大跨省异地就医直接结算范围 2019-08-11
  • 次仁卓玛一家的端午节 2019-08-11
  • 市人大常委会召开党组会议传达学习全国两会精神张轩主持并讲话 2019-08-09
  • 世界杯期间在家撸串的正确姿势-热门标签-华商网数码 2019-08-06
  • 来宝网Logo

    热门词:生物显微镜 水质分析仪 微波消解 荧光定量PCR 电化学工作站 生物安全柜

    现在位置时时彩网络平台>技术资料首页>行业动态>公司动态>MediciNova生物制药和Avigen生物医药确认合并

    南京大客车租赁: MediciNova生物制药和Avigen生物医药确认合并

    MediciNova2010年2月2日 20:00 点击:2616

    时时彩网络平台 www.qlgr.net
    MediciNova公司,一家生物制药公司,这是公开交易的纳斯达克全球市?。?Nasdaq代码: MNOV )和大力士市场大阪证券交易市?。ù氡嗪牛?4875 ) ,和Avigen公司( Nasdaq : AVGN ) ,一家生物制药公司,今天宣布,他们已经证实他们了解某些关键条款的建议收购Avigen由MediciNova ,将结合公司的广泛临床神经发展计划的基础上异丁司特( Avigen的AV - 411和MediciNova锰矿- 166 ) 。

    MediciNova和Avigen目前正在考虑这两个词的合并将提供该Avigen股东接受审议逼近Avigen的净现金清算价值加上300万美元。 Avigen股东将可以选择接受这种考虑现金关闭或收到兑换的安全,其中,现金审议可转换成股票在MediciNova转换价格等于更大的4.00美元或双方同意的数量加权平均价格MediciNova普通股。在结束18个月内,任何unexercised可转换债券将在其支付的现金价值。这将使两家公司股东有机会参与未来创造的价值,结合公司的产品组合。除了考虑上述情况,所有Avigen股东将获得一个特遣队付款的权利特定产品计划的里程碑付款与Avigen的转让协议的基因酶公司,可能受到一定的调整。

    雄一磐城,医学博士,哲学博士, MediciNova总裁兼首席执行干事说, “我们很高兴地宣布这一重要一步一个潜在的收购Avigen并认为拟议的合并提出了明确的优势,为两家公司股东,最值得注意的是,能够更充分地利用机会,异丁司特大院和类似物提供了各种迹象和市场。我们期待着最后确定的文件尽可能迅速,并介绍本次交易的股东的同意在适当的时候。 “

    “ Avigen认为,拟议中的合并的条件将是目前设想的最佳利益,我们的股东和我们打算继续进行谈判,目标是达成协定的所有条款,并提交给我们的股东批准在第三季度2009年, “安德鲁索特评论, Avigen公司的首席执行官,总裁和首席财务官。 “我们认为,结合我们异丁司特节目, AV411和Mn - 166 ,将加强全球发展潜力的化合物的一系列神经系统的迹象,包括多发性硬化症,神经性疼痛和吸毒。 ”

    达成的谅解是缔约方不具约束力的和受最终文件及尽职调查。关闭任何拟议中的合并也将取决于惯例成交条件,包括必要的股东和监管部门的批准,而且没有重大不利变化。 MediciNova和Avigen是没有法律义务继续讨论关于拟议中的交易的条款或此处所述的任何其他条款。没有明确的达成了协议,并不能有保证,最终协议将是成功的谈判,提议的条款将不会被修改或拟议中的合并将完成。

    关于MediciNova

    MediciNova ,公司是一家公开上市的生物制药公司,侧重于获取和发展新的,小分子疗法,用于治疗疾病的未满足的需要特别关注美国市场。通过战略联盟与日本主要的制药公司, MediciNova拥有权,多元化的投资组合的临床和临床前候选产品,每个MediciNova认为有一个良好的特点和不同的治疗资料,有吸引力的商业潜力和专利资产的说法有充分的商业范围。 MediciNova的管道包括6个临床阶段的化合物,用于治疗急性加重哮喘,多发性硬化症,哮喘,间质性膀胱炎,固体肿瘤的癌症,广泛性焦虑症,早产和尿失禁和前两个阶段的化合物,用于治疗血栓性疾病。 MediciNova目前的战略是集中资源,它的两个优先候选产品,美国明尼苏达- 221用于治疗急性加重哮喘和Mn - 166用于治疗多发性硬化症,要么追求发展独立的,如果锰- 221 ,或建立战略合作,以支持进一步发展,如锰166 。 MediciNova将寻求其他产品赚钱候选人键值拐点。欲了解更多有关MediciNova公司,请访问www.medicinova.com 。

    该MediciNova公司徽标可在//www.globenewswire.com/newsroom/prs/?pkgid=3135

    关于Avigen

    Avigen是一家生物制药公司,重点是查明和发展中国家不同的产品来治疗严重的神经系统和其他疾病。 Avigen正在寻求赚钱AV411和相关的候选药物,其潜在的产品神经痛和阿片撤离和阿片或甲基苯丙胺上瘾。欲了解更多有关Avigen ,咨询公司网站www.avigen.com 。

    该Avigen公司徽标可在//www.globenewswire.com/newsroom/prs/?pkgid=2981

    关于AV411

    在AV411组合,其中包括专有的类似物,代表新颖,一流,非阿片类药物,用于治疗疼痛和大量吸毒的迹象。 AV411目前正处于临床试验阶段2A条经费由国家药物滥用研究所。疼痛程序,根据美国FDA镇痛新药司,有望进入第二阶段的概念验证试验(县)在美国的基础上完成Avigen前和第1阶段和2a的临床试验。 Avigen最近完成的一个多星期的第一阶段试验在健康志愿者和糖尿病患者提供支持时的首选用药,高剂量方案。

    AV411是一种口服生物利用,中枢神经系统穿透,小分子胶质衰减抑制促炎细胞因子白细胞介素- 1β ,肿瘤坏死因子α和IL - 6 ,并可能上调抗炎细胞因子IL - 10 。它已被证明此外抑制行动从Toll样受体4 ( Toll样受体4 )刺激和细胞因子拮抗一挂钩系统性和neuroinflammation 。这些联合行动,被认为是调节其总体衰减neuroinflammation 。同时审议了一个新分子实体(非市场经济)在美国和欧洲,首次批准的药物在日本近20年前。该药物已订明,以超过100万哮喘患者,并有良好的上市后的安全性在日本雇用的剂量。

    MediciNova ,公司和Avigen ,公司及其董事和行政管理人员和其他人员,可被视为向与会者在任何代理人资格对拟议中的交易。有关MediciNova ,公司的董事和行政管理人员,可在其年度报告的表10 - K年度截至12月31日, 2008 ,这是提交给证券交易委员会在2009年3月31日,其代理的声明2009年年度股东大会,这是提交给证券交易委员会在2008年4月29日。有关Avigen ,公司的董事和行政管理人员,可在其年度报告10 - K表年度2008年12月31日,这是提交给证券交易委员会在2009年3月16日,经修订的4月30日2009年。其他有关参与者的任何代理招标,并说明其直接和间接的利益,安全控股或以其他方式,将载于任何委托书提交有关拟议中的交易。

    联系人: MediciNova公司
              慎麻子,首席财务官
               ( 858 ) 373-1500
               [email protected]

              接收通信有限责任公司
              朗达Chiger
               ( 917 ) 322-2569
               [email protected]

               Avigen公司
              安德鲁索特,行政总监,总裁兼
               财务总监
                 510-748-7172
              柯克约翰逊博士,副总裁,研究与发展
                 510-748-7106
               [email protected]

     

    推荐原始出处:

    MediciNova and Avigen Confirm Understanding for Key Terms for a Business Combination

    SAN DIEGO and ALAMEDA, Calif., June 25, 2009 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market (Nasdaq:MNOV) and the Hercules Market of the Osaka Securities Exchange (Code Number:4875), and Avigen, Inc. (Nasdaq:AVGN), a biopharmaceutical company, today announced that they have confirmed their understanding of certain key terms for a proposed acquisition of Avigen by MediciNova that would combine the companies' broad neurological clinical development programs based on ibudilast (Avigen's AV-411 and MediciNova's MN-166).

    MediciNova and Avigen currently contemplate that the terms of the merger would provide that Avigen shareholders receive consideration approximating Avigen's net cash liquidation value plus $3 million. Avigen shareholders would be able to elect to receive this consideration in cash at closing or to receive a convertible security by which that cash consideration may be converted into MediciNova stock at a conversion price equal to the greater of $4.00 or a mutually agreeable volume-weighted average price of MediciNova common stock. At the end of 18 months, any unexercised convertible securities would be paid out at their cash value. This would allow shareholders of both companies the opportunity to participate in the future value created by combining the companies' product portfolios. In addition to the consideration above, all Avigen shareholders would receive a contingent payment right for a specific product program milestone payment associated with Avigen's Assignment Agreement with Genzyme Corporation, potentially subject to certain adjustments.

    Yuichi Iwaki, M.D., Ph.D., MediciNova's President and Chief Executive Officer, said, "We are excited to announce this important step towards a potential acquisition of Avigen and believe that the proposed merger presents clear advantages for the shareholders of both companies, most notably, the ability to more fully take advantage of the opportunities that the ibudilast compound and analogs provide in a variety of indications and markets. We look forward to finalizing definitive documentation as expeditiously as possible and to presenting this transaction for shareholder approval in due course."

    "Avigen believes the proposed merger on the terms currently contemplated would be in the best interests of our shareholders and we intend to continue to negotiate with the goal of reaching agreement on all of the terms and presenting it to our shareholders for approval in the third quarter of 2009," commented Andrew Sauter, Avigen's Chief Executive Officer, President and Chief Financial Officer. "We believe that combining our ibudilast programs, AV411 and MN-166, would enhance the global development potential for the compound in a range of neurological indications, including Multiple Sclerosis, neuropathic pain and drug addiction."

    The understanding reached by the parties is nonbinding and subject to definitive documentation and due diligence. The closing of any proposed merger would also be subject to customary closing conditions, including required shareholder and regulatory approvals and the absence of material adverse changes. MediciNova and Avigen are not legally obligated to continue discussions regarding the proposed transaction on the terms described herein or on any other terms. No definitive agreements have been reached, and there can be no assurances that definitive agreements will be successfully negotiated, that the proposed terms will not be revised or that the proposed merger will be completed.

    About MediciNova

    MediciNova, Inc. is a publicly-traded biopharmaceutical company focused on acquiring and developing novel, small-molecule therapeutics for the treatment of diseases with unmet need with a specific focus on the U.S. market. Through strategic alliances primarily with Japanese pharmaceutical companies, MediciNova holds rights to a diversified portfolio of clinical and preclinical product candidates, each of which MediciNova believes has a well-characterized and differentiated therapeutic profile, attractive commercial potential and patent assets having claims of commercially adequate scope. MediciNova's pipeline includes six clinical-stage compounds for the treatment of acute exacerbations of asthma, multiple sclerosis, asthma, interstitial cystitis, solid tumor cancers, Generalized Anxiety Disorder, preterm labor and urinary incontinence and two preclinical-stage compounds for the treatment of thrombotic disorders. MediciNova's current strategy is to focus its resources on its two prioritized product candidates, MN-221 for the treatment of acute exacerbations of asthma and MN-166 for the treatment of multiple sclerosis, and either pursue development independently, in the case of MN-221, or establish a strategic collaboration to support further development, in the case of MN-166. MediciNova will seek to monetize its other product candidates at key value inflection points. For more information on MediciNova, Inc., please visit www.medicinova.com.

    The MediciNova, Inc. logo is available at //www.globenewswire.com/newsroom/prs/?pkgid=3135

    About Avigen

    Avigen is a biopharmaceutical company that has focused on identifying and developing differentiated products to treat patients with serious neurological and other disorders. Avigen is seeking to monetize AV411 and related drug candidates, its potential product for neuropathic pain and opioid withdrawal and opioid or methamphetamine addiction. For more information about Avigen, consult the company's website at www.avigen.com.

    The Avigen, Inc. logo is available at //www.globenewswire.com/newsroom/prs/?pkgid=2981

    About AV411

    The AV411 portfolio, which includes proprietary analogs, represents novel, first-in-class, non-opioid drugs for the treatment of significant pain and drug addiction indications. AV411 is currently in a Phase 2a clinical trial funded by the National Institute on Drug Abuse. The pain program, under a FDA Analgesia Division IND, is poised to enter Phase 2 proof-of-concept trial(s) in the United States based on completed Avigen preclinical and Phase 1 and 2a clinical trials. Avigen most recently completed a multi-week Phase 1 trial in both healthy volunteers and diabetic patients which provides support for dosing at preferred, high dose regimens.

    AV411 is an orally bioavailable, CNS-penetrating, small molecule glial attenuator that suppresses pro-inflammatory cytokines IL-1 beta, TNF alpha, and IL-6, and may upregulate the anti-inflammatory cytokine IL-10. It has additionally been shown to inhibit actions from toll-like receptor 4 (TLR4) stimulation and to antagonize a cytokine linked to systemic and neuroinflammation. These combined actions are thought to mediate its overall attenuation of neuroinflammation. While considered a New Molecular Entity (NME) in the United States and Europe, the drug was first approved in Japan nearly 20 years ago. The drug has been prescribed to over one million asthma patients and has a good post-marketing safety profile at the doses employed in Japan.

    MediciNova, Inc. and Avigen, Inc. and their directors and executive officers and other persons may be deemed to be participants in any solicitation of proxies in respect of the proposed transaction. Information regarding MediciNova, Inc.'s directors and executive officers is available in its Annual Report on Form 10-K for the year ended December 31, 2008, which was filed with the SEC on March 31, 2009, and its proxy statement for its 2009 annual meeting of stockholders, which was filed with the SEC on April 29, 2008. Information regarding Avigen, Inc.'s directors and executive officers is available in its Annual Report on Form 10-K for the year ended December 31, 2008, which was filed with the SEC on March 16, 2009, as amended on April 30, 2009. Other information regarding the participants in any proxy solicitation and a description of their direct and indirect interests, by security holdings or otherwise, will be contained in any proxy statement filed in connection with the proposed transaction.

    CONTACT:  MediciNova, Inc.
              Shintaro Asako, Chief Financial Officer
              (858) 373-1500
              [email protected]

              Rx Communications, LLC
              Rhonda Chiger
              (917) 322-2569
              [email protected]

              Avigen, Inc.
              Andrew Sauter, Chief Executive Officer, President and Chief
               Financial Officer
                510-748-7172
              Kirk Johnson, Ph.D., Vice President, Research & Development
                510-748-7106
              [email protected]

    (来源: MediciNova )


    全年征稿 / 资讯合作

    联系邮箱:[email protected]

    版权与免责声明

    • 凡本网注明“来源:来宝网”的所有作品,版权均属于来宝网,转载请必须注明来宝网, 时时彩网络平台,违反者本网将追究相关法律责任。
    • 本网转载并注明自其它来源的作品,目的在于传递更多信息,并不代表本网赞同其观点或证实其内容的真实性,不承担此类作品侵权行为的直接责任及连带责任。其他媒体、网站或个人从本网转载时,必须保留本网注明的作品来源,并自负版权等法律责任。
    • 如涉及作品内容、版权等问题,请在作品发表之日起一周内与本网联系,否则视为放弃相关权利。


  • 中国资本市场开放出大招 跨境证券投资更便利 2019-10-13
  • 世卫将“游戏障碍”列为新疾病 哪些症状可被确诊? 2019-10-13
  • 景区去门票化积弊短期难除 如何摆脱门票依赖? 2019-10-08
  • 东风路老旧小区欲华丽变身 微改造项目勘察设计已招标 ——凤凰网房产广州 2019-10-08
  • 翔龙无人机服役后首次曝光,大幅提升空军情报收集能力 2019-09-19
  • 证监会去年对外公开监管信息14560条 2019-09-19
  • 人民网欧洲中心分社记者报道集 2019-09-06
  • 图解:短视频平台频遭约谈敲响警钟,野蛮生长要不得! 2019-09-06
  • 中考期间广州部分公交线路有调整 2019-09-01
  • 减肥必备!这十种食物饱口福还能吃出好身材 2019-09-01
  • “蛟龙” 吸引世界目光(砥砺奋进的五年·重大工程巡礼) 2019-08-19
  • 李克强:扩大跨省异地就医直接结算范围 2019-08-11
  • 次仁卓玛一家的端午节 2019-08-11
  • 市人大常委会召开党组会议传达学习全国两会精神张轩主持并讲话 2019-08-09
  • 世界杯期间在家撸串的正确姿势-热门标签-华商网数码 2019-08-06
  • ag平台网址有哪些 提现的百人牛牛下载 快乐飞艇实时开奖 大乐透合买奖金分配比列表 山西快乐十分开奖结果查询结果 捕鱼机68000w 12选5期期中奖的万能码 体彩大乐透带坐标连线标准走势图 11选5选号技巧 ag真人娱乐平台 手机棋牌游戏龙虎怎么赢钱 类似试客小兵赚钱软件 山东时时彩玩法 装甲战争为什么没人玩 安卓系统拳击游戏排行